Roozbeh Mohajer, MD
Hematology/Oncology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mohajer’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A110400 · Current
Licensed to practise in California · since 2009 · expires 2027-05-31 · Shahid Beheshti University of Medical Sciences.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,750,014
Medicare paid this office $2,750,014 for 826 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $408,581 | None |
| Injection, pembrolizumab, 1 mg | 15 | $376,508 | None |
| Injection, denosumab, 1 mg | 29 | $151,231 | None |
| Long return visit (40+ min) | 211 | $129,640 | $170 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 68 | $68,592 | None |
See all 31 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $408,581 | None |
| Injection, pembrolizumab, 1 mg | 15 | $376,508 | None |
| Injection, denosumab, 1 mg | 29 | $151,231 | None |
| Long return visit (40+ min) | 211 | $129,640 | $170 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 68 | $68,592 | None |
| Injection, romosozumab-aqqg, 1 mg | 12 | $63,706 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $59,211 | None |
| Return visit (30+ min) | 359 | $57,708 | $110 |
| Administration of chemotherapy into vein, 1 hour or less | 58 | $21,969 | $141 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 129 | $12,237 | $67 |
| New patient visit (60+ min) | 47 | $9,608 | $204 |
| New patient visit (45+ min) | 48 | $7,421 | $155 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 290 | $7,288 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 76 | $7,231 | $37 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $6,619 | $78 |
| Bcg live intravesical instillation, 1 mg | 16 | $3,623 | None |
| Instillation of anti-cancer drug into bladder | 17 | $2,949 | $84 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $2,885 | $69 |
| Injection of drug or substance under skin or into muscle | 67 | $2,873 | $14 |
| Injection, zoledronic acid, 1 mg | 100 | $2,455 | None |
| Injection of drug or substance into vein | 54 | $2,237 | $37 |
| Drawing of blood for a medical problem | 12 | $2,230 | $101 |
| Injection of additional new drug or substance into vein | 38 | $1,931 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 20 | $1,768 | $21 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $1,074 | $24 |
| Administration of chemotherapy into vein, each additional hour | 14 | $868 | $29 |
| Irrigation of implanted venous access drug delivery device | 15 | $635 | $26 |
| Injection, ondansetron hydrochloride, per 1 mg | 19 | $62 | None |
| Infusion, normal saline solution, 250 cc | 94 | $56 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 20 | $54 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $23 | None |
Who their Medicare patients are
826 Original Medicare patients in 2024. Average age 78 · Under 65 2% · 85 and older 22% · Women 50% · Also on Medicaid 6% · Health risk score 1.41. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 65% · Cancer 39% · Coronary heart disease 28% · Chronic kidney disease 23% · Atrial fibrillation 21% · Diabetes 19% · Heart failure 14% · Depression 13% · COPD 8% · Dementia 7% · Stroke 5%.
The office billed $8,380,688, Medicare allowed $3,467,053 and paid $2,750,014; for 115,967 services of 111 kinds; $2,423,477 of it was for drugs given in the office and $326,537 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 826 | 115,967 | 78 | 1.41 | $8,380,688 | $2,750,014 |
| 2023 | 793 | 156,946 | 78 | 1.39 | $9,759,583 | $3,131,960 |
| 2022 | 737 | 148,849 | 78 | 1.38 | $8,888,017 | $2,899,792 |
| 2021 | 588 | 88,433 | 77 | 1.39 | $4,484,661 | $1,409,599 |
| 2020 | 492 | 70,817 | 76 | 1.42 | $4,290,075 | $1,406,751 |
| 2019 | 432 | 60,238 | 76 | 1.43 | $3,167,666 | $1,047,109 |
| 2018 | 204 | 761 | 78 | 1.88 | $284,047 | $61,345 |
| 2017 | 189 | 415 | 76 | 2.32 | $78,613 | $34,409 |
| 2016 | 366 | 1,312 | 75 | 1.80 | $179,437 | $89,817 |
| 2015 | 369 | 1,229 | 74 | 1.71 | $164,814 | $86,206 |
| 2014 | 128 | 160 | 74 | 1.60 | $18,243 | $10,275 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 35 services
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $485,386 | None |
| Injection, pembrolizumab, 1 mg | 15 | $413,460 | None |
| Injection, denosumab, 1 mg | 29 | $152,248 | None |
| Injection, vedolizumab, intravenous, 1 mg | 15 | $150,354 | None |
| Long return visit (40+ min) | 208 | $126,487 | $169 |
| Injection, tocilizumab, 1 mg | 14 | $81,984 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 64 | $57,963 | None |
| Return visit (30+ min) | 270 | $47,177 | $115 |
| Administration of chemotherapy into vein, 1 hour or less | 88 | $41,731 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 133 | $15,702 | $69 |
| New patient visit (60+ min) | 62 | $12,770 | $206 |
| New patient visit (45+ min) | 81 | $11,515 | $142 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $8,348 | $80 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 70 | $6,285 | $37 |
| Bcg live intravesical instillation, 1 mg | 17 | $5,217 | None |
| Instillation of anti-cancer drug into bladder | 17 | $4,142 | $86 |
| Injection of additional new drug or substance into vein | 51 | $4,077 | $17 |
| Short return visit (20+ min) | 45 | $3,779 | $82 |
| Administration of additional new drug or substance into vein, 1 hour or less | 20 | $3,535 | $71 |
| Administration of chemotherapy into vein, each additional hour | 41 | $3,440 | $30 |
| Injection of drug or substance under skin or into muscle | 61 | $3,094 | $14 |
| Injection, zoledronic acid, 1 mg | 93 | $2,976 | None |
| Injection of drug or substance into vein | 54 | $2,589 | $40 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 48 | $2,415 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $2,395 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 22 | $2,175 | $31 |
| Drawing of blood for a medical problem | 12 | $1,503 | $100 |
| New patient visit (30+ min) | 13 | $1,423 | $109 |
| Injection, fosaprepitant, 1 mg | 11 | $527 | None |
| Irrigation of implanted venous access drug delivery device | 12 | $456 | $29 |
| Infusion into a vein for hydration, each additional hour | 15 | $433 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 38 | $131 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 31 | $109 | None |
| Infusion, normal saline solution, 250 cc | 111 | $71 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 22 | $49 | None |
2022: 33 services
| Injection, pembrolizumab, 1 mg | 16 | $599,167 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 13 | $397,504 | None |
| Long return visit (40+ min) | 234 | $133,279 | $168 |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 12 | $89,412 | None |
| Injection, denosumab, 1 mg | 23 | $70,358 | None |
| Leuprolide acetate (for depot suspension), 7.5 mg | 64 | $47,862 | None |
| Return visit (30+ min) | 257 | $46,859 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 103 | $44,931 | $150 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 12 | $44,375 | $148 |
| Injection, infliximab, excludes biosimilar, 10 mg | 13 | $42,152 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 103 | $15,715 | $73 |
| New patient visit (60+ min) | 60 | $12,294 | $205 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $11,060 | $83 |
| New patient visit (45+ min) | 72 | $10,712 | $149 |
| Administration of additional new drug or substance into vein, 1 hour or less | 32 | $7,814 | $73 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 71 | $5,566 | $35 |
| Bcg live intravesical instillation, 1 mg | 15 | $4,809 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 36 | $3,780 | $32 |
| Short return visit (20+ min) | 49 | $3,777 | $74 |
| Injection of additional new drug or substance into vein | 57 | $3,648 | $17 |
| Instillation of anti-cancer drug into bladder | 15 | $3,317 | $87 |
| Administration of chemotherapy into vein, each additional hour | 36 | $3,305 | $31 |
| Drawing of blood for a medical problem | 15 | $3,144 | $112 |
| Injection of drug or substance under skin or into muscle | 59 | $2,365 | $14 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 18 | $2,139 | $22 |
| Injection, zoledronic acid, 1 mg | 67 | $1,849 | None |
| Injection of drug or substance into vein | 37 | $1,700 | $43 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 50 | $1,541 | $23 |
| Injection, fosaprepitant, 1 mg | 20 | $761 | None |
| Injection, carboplatin, 50 mg | 15 | $524 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 42 | $113 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 38 | $92 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 27 | $59 | None |
2021: 29 services
| Return visit (30+ min) | 290 | $91,170 | $119 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 11 | $54,331 | $189 |
| Injection, denosumab, 1 mg | 13 | $31,947 | None |
| Administration of chemotherapy into vein, 1 hour or less | 72 | $29,284 | $161 |
| Long return visit (40+ min) | 91 | $26,397 | $170 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 31 | $19,743 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 73 | $12,098 | $79 |
| New patient visit (60+ min) | 55 | $11,741 | $213 |
| New patient visit (45+ min) | 65 | $10,239 | $158 |
| Short return visit (20+ min) | 64 | $5,173 | $75 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $4,580 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 33 | $3,587 | $34 |
| Bcg live intravesical instillation, 1 mg | 13 | $3,409 | None |
| Injection of additional new drug or substance into vein | 50 | $3,141 | $18 |
| Drawing of blood for a medical problem | 11 | $2,515 | $120 |
| Instillation of anti-cancer drug into bladder | 13 | $2,483 | $89 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 37 | $2,416 | $35 |
| Administration of chemotherapy into vein, each additional hour | 30 | $2,314 | $33 |
| Administration of additional new drug or substance into vein using push technique | 15 | $2,137 | $67 |
| Injection, zoledronic acid, 1 mg | 37 | $1,484 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $1,465 | $23 |
| Injection of drug or substance into vein | 26 | $1,390 | $43 |
| Injection of drug or substance under skin or into muscle | 46 | $1,292 | $14 |
| Injection, fosaprepitant, 1 mg | 17 | $1,226 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 32 | $1,068 | $24 |
| Injection, paclitaxel, 1 mg | 11 | $521 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 40 | $130 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 31 | $87 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 24 | $44 | None |
2020: 28 services
| Injection, infliximab, excludes biosimilar, 10 mg | 13 | $41,909 | None |
| Return visit (30+ min) | 208 | $39,840 | $96 |
| Injection, denosumab, 1 mg | 15 | $27,477 | None |
| Administration of chemotherapy into vein, 1 hour or less | 70 | $23,854 | $150 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $12,774 | None |
| New patient visit (45+ min) | 86 | $12,361 | $144 |
| Long return visit (40+ min) | 56 | $8,973 | $130 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 52 | $7,701 | $74 |
| Short return visit (20+ min) | 60 | $5,034 | $69 |
| New patient visit (60+ min) | 23 | $4,458 | $194 |
| Administration of additional new drug or substance into vein, 1 hour or less | 21 | $4,341 | $72 |
| Telephone medical discussion with physician, 21-30 minutes | 34 | $4,217 | $103 |
| Administration of chemotherapy into vein, each additional hour | 28 | $3,275 | $31 |
| Bcg live intravesical instillation, 1 mg | 12 | $2,670 | None |
| Injection of additional new drug or substance into vein | 42 | $2,089 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 25 | $2,048 | $32 |
| Instillation of anti-cancer drug into bladder | 13 | $1,937 | $77 |
| Telephone medical discussion with physician, 11-20 minutes | 23 | $1,832 | $73 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,419 | $22 |
| Injection of drug or substance under skin or into muscle | 44 | $1,346 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $822 | $33 |
| Injection of drug or substance into vein | 13 | $792 | $40 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 13 | $748 | None |
| Injection, zoledronic acid, 1 mg | 19 | $677 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $601 | $23 |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $68 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 29 | $64 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $19 | None |
2019: 26 services
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $66,473 | None |
| Injection, infliximab, excludes biosimilar, 10 mg | 15 | $59,160 | None |
| Injection, denosumab, 1 mg | 15 | $39,265 | None |
| Long return visit (40+ min) | 113 | $19,762 | $136 |
| Return visit (30+ min) | 122 | $19,108 | $104 |
| Administration of chemotherapy into vein, 1 hour or less | 64 | $19,099 | $149 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 61 | $10,237 | $76 |
| New patient visit (45+ min) | 57 | $8,772 | $154 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $7,935 | None |
| New patient visit (60+ min) | 37 | $7,186 | $194 |
| Administration of additional new drug or substance into vein, 1 hour or less | 16 | $2,878 | $72 |
| Administration of chemotherapy into vein, each additional hour | 31 | $2,482 | $31 |
| Drawing of blood for a medical problem | 14 | $2,368 | $108 |
| Short return visit (20+ min) | 25 | $2,298 | $72 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $1,896 | $22 |
| New patient visit (30+ min) | 16 | $1,659 | $104 |
| Injection of additional new drug or substance into vein | 43 | $1,620 | $17 |
| Injection of drug or substance under skin or into muscle | 34 | $1,601 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 24 | $1,256 | $32 |
| Injection, zoledronic acid, 1 mg | 23 | $1,040 | None |
| Injection of drug or substance into vein | 20 | $898 | $41 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 18 | $557 | $23 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $546 | $32 |
| Injection, dexamethasone sodium phosphate, 1 mg | 32 | $66 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 22 | $60 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 20 | $19 | None |
2018: 9 services
| Return visit (30+ min) | 99 | $23,309 | $68 |
| Long return visit (40+ min) | 67 | $14,402 | $94 |
| New patient visit (45+ min) | 66 | $7,070 | $107 |
| New patient visit (60+ min) | 32 | $4,319 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,827 | $91 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,862 | $119 |
| Short return visit (20+ min) | 33 | $2,259 | $43 |
| New patient visit (30+ min) | 25 | $1,563 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,307 | $65 |
2017: 6 services
| Return visit (30+ min) | 123 | $13,931 | $71 |
| Long return visit (40+ min) | 54 | $10,040 | $108 |
| Return visit (30+ min) | 23 | $2,539 | $71 |
| New patient visit (45+ min) | 18 | $2,079 | $116 |
| Short return visit (20+ min) | 13 | $776 | $46 |
| Short return visit (20+ min) | 12 | $562 | $47 |
2016: 9 services
| Long return visit (40+ min) | 95 | $22,147 | $84 |
| Return visit (30+ min) | 182 | $20,822 | $63 |
| Return visit (30+ min) | 197 | $18,394 | $57 |
| Long return visit (40+ min) | 61 | $10,054 | $89 |
| New patient visit (60+ min) | 40 | $5,396 | $135 |
| Short return visit (20+ min) | 77 | $3,520 | $41 |
| Short return visit (20+ min) | 64 | $2,816 | $39 |
| New patient visit (45+ min) | 24 | $2,136 | $89 |
| New patient visit (60+ min) | 13 | $1,775 | $137 |
2015: 8 services
| Long return visit (40+ min) | 127 | $32,917 | $86 |
| Return visit (30+ min) | 254 | $29,370 | $59 |
| New patient visit (60+ min) | 62 | $8,287 | $134 |
| Short return visit (20+ min) | 116 | $6,331 | $39 |
| New patient visit (45+ min) | 43 | $4,378 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,287 | $163 |
| New patient visit (30+ min) | 19 | $1,104 | $58 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 23 | $171 | $7 |
2014: 4 services
| Return visit (30+ min) | 51 | $3,682 | $62 |
| Short return visit (20+ min) | 56 | $2,457 | $41 |
| Long return visit (40+ min) | 19 | $1,879 | $89 |
| New patient visit (60+ min) | 11 | $1,495 | $136 |
Medicaid work
$93 in 2024
Medicaid paid $93 for 14 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 14 | $93 |
| 2024 | 14 | 1 | 13 | $93 |
| 2023 | 17 | 1 | 13 | $43 |
| 2021 | 49 | 1 | 16 | $637 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 17 | $43 |
2021
| Return visit (30+ min) | 49 | $637 |
Drugs they prescribed that Part D paid
$3,140,901
Pharmacies billed $3,140,901 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (26 of 1,194) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
865 generic and 329 brand-name prescriptions · $3,140,901 in drug cost · 52 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 40 | $409,247 | $10,231 |
| Tagrisso | 20 | $346,643 | $17,332 |
| Inlyta | 13 | $319,602 | $24,585 |
| Erleada | 19 | $309,924 | $16,312 |
| Calquence | 24 | $292,947 | $12,206 |
See all 29 drugs
| Brukinsa | 40 | $409,247 | $10,231 |
| Tagrisso | 20 | $346,643 | $17,332 |
| Inlyta | 13 | $319,602 | $24,585 |
| Erleada | 19 | $309,924 | $16,312 |
| Calquence | 24 | $292,947 | $12,206 |
| Imbruvica | 18 | $279,097 | $15,505 |
| Lenalidomide | 11 | $166,298 | $15,118 |
| Abiraterone Acetate | 132 | $103,422 | $783 |
| Eliquis | 73 | $71,610 | $981 |
| Xarelto | 34 | $54,746 | $1,610 |
| Imatinib Mesylate | 13 | $12,117 | $932 |
| Letrozole | 79 | $2,330 | $29 |
| Exemestane | 23 | $1,957 | $85 |
| Hydroxyurea | 47 | $1,277 | $27 |
| Prednisone | 149 | $912 | $6 |
| Tamoxifen Citrate | 35 | $747 | $21 |
| Acyclovir | 52 | $640 | $12 |
| Potassium Chloride | 16 | $377 | $24 |
| Dexamethasone | 16 | $370 | $23 |
| Prochlorperazine Maleate | 42 | $368 | $9 |
| Levothyroxine | 24 | $358 | $15 |
| Ondansetron | 28 | $244 | $9 |
| Sulfamethoxazole-Trimethoprim | 50 | $209 | $4 |
| Allopurinol | 12 | $192 | $16 |
| Anastrozole | 14 | $175 | $13 |
| Tamsulosin | 11 | $159 | $14 |
| Mirtazapine | 16 | $153 | $10 |
| Lorazepam | 12 | $29 | $2 |
| Tramadol | 17 | $22 | $1 |
Year by year
| 2024 | 1,194 | 201 | 2% (26) | 28% | $3,140,901 |
| 2023 | 1,200 | 189 | 3% (38) | 27% | $2,762,695 |
| 2022 | 1,114 | 179 | 3% (31) | None | $3,056,096 |
| 2021 | 686 | 112 | None | 33% | $1,838,092 |
| 2020 | 561 | 91 | 3% (19) | 27% | $1,156,162 |
| 2019 | 259 | 57 | 9% (22) | None | $277,121 |
| 2018 | 225 | 37 | 8% (17) | None | $359,671 |
| 2017 | 335 | 93 | 9% (29) | 17% | $601,535 |
| 2016 | 846 | 129 | 14% (116) | 20% | $1,406,393 |
| 2015 | 587 | 123 | 8% (49) | 18% | $786,539 |
| 2014 | 64 | 32 | 23% (15) | 20% | $45,807 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 35 drugs
| Imbruvica | 22 | $377,369 | $17,153 |
| Erleada | 24 | $375,167 | $15,632 |
| Brukinsa | 23 | $259,433 | $11,280 |
| Revlimid | 12 | $212,422 | $17,702 |
| Pemazyre | 11 | $199,377 | $18,125 |
| Ibrance | 11 | $186,590 | $16,963 |
| Xtandi | 12 | $181,564 | $15,130 |
| Nubeqa | 16 | $136,613 | $8,538 |
| Abiraterone Acetate | 119 | $104,312 | $877 |
| Xarelto | 37 | $59,336 | $1,604 |
| Imatinib Mesylate | 12 | $59,039 | $4,920 |
| Eliquis | 55 | $53,886 | $980 |
| Creon | 22 | $22,603 | $1,027 |
| Exemestane | 35 | $8,547 | $244 |
| Letrozole | 69 | $2,485 | $36 |
| Potassium Chloride | 18 | $2,150 | $119 |
| Hydroxyurea | 39 | $1,782 | $46 |
| Acyclovir | 49 | $1,023 | $21 |
| Prednisone | 123 | $938 | $8 |
| Tamoxifen Citrate | 30 | $834 | $28 |
| Dexamethasone | 26 | $786 | $30 |
| Prochlorperazine Maleate | 67 | $775 | $12 |
| Tranexamic Acid | 11 | $635 | $58 |
| Levothyroxine | 24 | $466 | $19 |
| Ondansetron | 34 | $451 | $13 |
| Loperamide | 11 | $311 | $28 |
| Tamsulosin | 15 | $253 | $17 |
| Gabapentin | 11 | $187 | $17 |
| Anastrozole | 11 | $178 | $16 |
| Pantoprazole | 14 | $154 | $11 |
| Sulfamethoxazole-Trimethoprim | 28 | $140 | $5 |
| Lorazepam | 22 | $136 | $6 |
| Hydrochlorothiazide | 16 | $75 | $5 |
| Furosemide | 14 | $42 | $3 |
| Tramadol | 13 | $38 | $3 |
2022: 32 drugs
| Imbruvica | 26 | $402,030 | $15,463 |
| Revlimid | 23 | $346,630 | $15,071 |
| Venclexta | 22 | $257,550 | $11,707 |
| Xtandi | 18 | $253,436 | $14,080 |
| Nubeqa | 23 | $227,139 | $9,876 |
| Ibrance | 15 | $226,306 | $15,087 |
| Brukinsa | 13 | $195,235 | $15,018 |
| Erleada | 13 | $192,314 | $14,793 |
| Calquence | 11 | $172,100 | $15,645 |
| Imatinib Mesylate | 12 | $66,918 | $5,577 |
| Eliquis | 47 | $51,006 | $1,085 |
| Xarelto | 40 | $46,379 | $1,159 |
| Abiraterone Acetate | 47 | $31,040 | $660 |
| Creon | 11 | $12,644 | $1,149 |
| Exemestane | 27 | $6,698 | $248 |
| Letrozole | 81 | $2,261 | $28 |
| Hydroxyurea | 31 | $1,599 | $52 |
| Dexamethasone | 35 | $885 | $25 |
| Prochlorperazine Maleate | 74 | $853 | $12 |
| Acyclovir | 43 | $788 | $18 |
| Prednisone | 104 | $720 | $7 |
| Tamoxifen Citrate | 29 | $701 | $24 |
| Ondansetron | 35 | $555 | $16 |
| Levothyroxine | 15 | $333 | $22 |
| Venlafaxine Hcl Er | 15 | $252 | $17 |
| Potassium Chloride | 14 | $249 | $18 |
| Gabapentin | 19 | $248 | $13 |
| Pantoprazole | 17 | $197 | $12 |
| Tamsulosin | 16 | $180 | $11 |
| Hydrocodone-Acetaminophen | 17 | $143 | $8 |
| Lorazepam | 14 | $96 | $7 |
| Sulfamethoxazole-Trimethoprim | 29 | $94 | $3 |
2021: 22 drugs
| Imbruvica | 26 | $383,334 | $14,744 |
| Erleada | 24 | $313,522 | $13,063 |
| Xtandi | 22 | $286,033 | $13,001 |
| Nubeqa | 19 | $231,175 | $12,167 |
| Calquence | 13 | $198,430 | $15,264 |
| Imatinib Mesylate | 11 | $87,366 | $7,942 |
| Xarelto | 47 | $37,098 | $789 |
| Eliquis | 26 | $26,641 | $1,025 |
| Abiraterone Acetate | 15 | $12,230 | $815 |
| Exemestane | 16 | $3,689 | $231 |
| Hydroxyurea | 39 | $2,146 | $55 |
| Letrozole | 56 | $2,026 | $36 |
| Prochlorperazine Maleate | 55 | $834 | $15 |
| Ondansetron | 28 | $689 | $25 |
| Dexamethasone | 26 | $596 | $23 |
| Prednisone | 51 | $465 | $9 |
| Potassium Chloride | 11 | $343 | $31 |
| Gabapentin | 21 | $323 | $15 |
| Tamoxifen Citrate | 11 | $261 | $24 |
| Levothyroxine | 12 | $247 | $21 |
| Lorazepam | 20 | $102 | $5 |
| Sulfamethoxazole-Trimethoprim | 11 | $71 | $6 |
2020: 17 drugs
| Revlimid | 29 | $435,877 | $15,030 |
| Imbruvica | 16 | $213,333 | $13,333 |
| Imatinib Mesylate | 12 | $98,395 | $8,200 |
| Eliquis | 34 | $22,870 | $673 |
| Xarelto | 25 | $20,800 | $832 |
| Hydroxyurea | 48 | $2,060 | $43 |
| Letrozole | 49 | $1,350 | $28 |
| Dexamethasone | 42 | $818 | $19 |
| Prochlorperazine Maleate | 39 | $514 | $13 |
| Anastrozole | 14 | $451 | $32 |
| Acyclovir | 15 | $372 | $25 |
| Ondansetron | 15 | $313 | $21 |
| Allopurinol | 12 | $243 | $20 |
| Levothyroxine | 13 | $229 | $18 |
| Prednisone | 43 | $197 | $5 |
| Lorazepam | 17 | $117 | $7 |
| Hydrocodone-Acetaminophen | 11 | $81 | $7 |
2019: 8 drugs
| Anastrozole | 17 | $438 | $26 |
| Hydroxyurea | 12 | $330 | $28 |
| Levothyroxine | 13 | $267 | $21 |
| Ondansetron | 14 | $235 | $17 |
| Letrozole | 14 | $178 | $13 |
| Prednisone | 27 | $171 | $6 |
| Prochlorperazine Maleate | 14 | $168 | $12 |
| Lorazepam | 12 | $73 | $6 |
2018: 3 drugs
| Xtandi | 14 | $153,220 | $10,944 |
| Letrozole | 33 | $512 | $16 |
| Lorazepam | 16 | $95 | $6 |
2017: 5 drugs
| Revlimid | 15 | $208,001 | $13,867 |
| Anastrozole | 85 | $1,327 | $16 |
| Letrozole | 16 | $199 | $12 |
| Hydrocodone-Acetaminophen | 11 | $123 | $11 |
| Lorazepam | 11 | $64 | $6 |
2016: 23 drugs
| Gleevec | 33 | $466,155 | $14,126 |
| Revlimid | 33 | $421,243 | $12,765 |
| Xtandi | 12 | $110,850 | $9,238 |
| Exemestane | 13 | $4,198 | $323 |
| Anastrozole | 154 | $2,890 | $19 |
| Hydroxyurea | 45 | $1,696 | $38 |
| Fentanyl | 18 | $1,336 | $74 |
| Oxycodone-Acetaminophen | 15 | $1,228 | $82 |
| Ondansetron | 40 | $1,224 | $31 |
| Tamoxifen Citrate | 27 | $1,123 | $42 |
| Hydrocodone-Acetaminophen | 40 | $1,033 | $26 |
| Morphine Sulfate Er | 16 | $937 | $59 |
| Morphine Sulfate | 15 | $459 | $31 |
| Dexamethasone | 19 | $367 | $19 |
| Prednisone | 30 | $220 | $7 |
| Gabapentin | 19 | $199 | $10 |
| Levothyroxine | 14 | $180 | $13 |
| Lorazepam | 22 | $180 | $8 |
| Letrozole | 16 | $137 | $9 |
| Mirtazapine | 12 | $126 | $11 |
| Omeprazole | 13 | $77 | $6 |
| Metoprolol | 15 | $54 | $4 |
| Furosemide | 15 | $36 | $2 |
2015: 13 drugs
| Gleevec | 14 | $254,801 | $18,200 |
| Revlimid | 12 | $148,957 | $12,413 |
| Zytiga | 11 | $83,948 | $7,632 |
| Exemestane | 21 | $9,379 | $447 |
| Anastrozole | 117 | $2,071 | $18 |
| Hydroxyurea | 42 | $1,976 | $47 |
| Fentanyl | 16 | $1,624 | $101 |
| Ondansetron | 30 | $1,382 | $46 |
| Tamoxifen Citrate | 29 | $1,269 | $44 |
| Hydrocodone-Acetaminophen | 19 | $455 | $24 |
| Letrozole | 17 | $298 | $18 |
| Prednisone | 37 | $250 | $7 |
| Levothyroxine | 19 | $221 | $12 |
Money from drug and device companies
$603 in 2025
| 2025 | 7 | 15 | None | $603 |
| 2024 | 9 | 13 | $2,220 | $2,872 |
| 2023 | 3 | 4 | None | $294 |
| 2022 | 3 | 3 | None | $167 |
| 2021 | 3 | 3 | None | $122 |
| 2019 | 4 | 4 | None | $68 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $313 | 5 payments
|
| Abbvie | Epkinly | $123 | 1 payment
|
| Daiichi Sankyo | Enhertu | $72 | 3 payments
|
| Caris MPI | Mi Cancer Seek | $30 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $23 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
See all 13 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-18 | Enhertu | $23 |
| Daiichi Sankyo | Meals · 2025-11-21 | Datroway | $22 |
| Iovance Biotherapeutics | Meals · 2025-10-07 | Amtagvi | $21 |
| Daiichi Sankyo | Meals · 2025-06-27 | Enhertu | $21 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-19 | Atacand | $133 |
| Abbvie | Meals · 2025-06-18 | Epkinly | $123 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-14 | Enhertu | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-14 | Enhertu | $8 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-06 | Enhertu | $123 |
| Caris MPI | Meals · 2025-05-05 | Mi Cancer Seek | $30 |
| GlaxoSmithKline | Meals · 2025-03-25 | Ojjaara | $23 |
| Daiichi Sankyo | Meals · 2025-03-25 | Enhertu | $29 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-12 | Nubeqa | $22 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $2,872
| AstraZeneca Pharmaceuticals LP | Lynparza | $2,382 | 2 payments
|
| Abbvie | Epkinly | $150 | 2 payments
|
| Aveo Pharmaceuticals | Fotivda | $90 | 1 payment
|
| Janssen Biotech | Darzalex | $82 | 2 payments
|
| Daiichi Sankyo | Enhertu | $55 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $33 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $33 | 1 payment
|
| GlaxoSmithKline | Ojjaara | $27 | 1 payment
|
| Lilly USA | Jaypirca | $20 | 1 payment
|
2023: $294
| Pharmacyclics LLC An AbbVie | Imbruvica | $144 | 2 payments
|
| Incyte | Jakafi | $125 | 1 payment
|
| Pfizer | Ibrance | $25 | 1 payment
|
2022: $167
| GlaxoSmithKline | Zejula | $114 | 1 payment
|
| Pfizer | Ibrance | $32 | 1 payment
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $21 | 1 payment
|
2021: $122
| Novocure | Optune | $76 | 1 payment
|
| Boston Scientific | Spaceoar Vue | $34 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2019: $68
| Lilly USA | Alimta | $24 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $20 | 1 payment
|
| Seattle Genetics | Adcetris | $12 | 1 payment
|
| Pfizer | Ibrance | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With A Covalent Bruton Tyrosine Kinase Inhibitor · 2025 | Their institution | $19,410 |
| Eli Lilly and Company · A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With A Covalent Bruton Tyrosine Kinase Inhibitor · 2024 | This clinician | $1,307 |
| Eli Lilly and Company · A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With A Covalent Bruton Tyrosine Kinase Inhibitor · 2025 | This clinician | $291 |
Professional record
- NPI
- 1457538449
- Licence
- CA A110400California A110400: Current · expires 2027-05-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X); Federal specialty code 207RH0002X (207RH0002X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2008-01-22
- NPI last updated
- 2020-06-03
- NPI record certified
- 2020-06-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 2505 Samaritan Dr, San Jose, CA, 95124